2025-07-05 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co Inc (MRK) based on the provided data, structured for clarity and actionable insights.

## Merck & Co Inc (MRK) Stock Analysis

**Merck & Co Inc** is a global pharmaceutical company that develops and markets a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -2.95%
*   **VOO Cumulative Return:** 95.42%
*   **Disparity:** -97.2 (Max: 23.1, Min: -99.5, Relative Disparity: 1.9)

**Analysis:** MRK has significantly underperformed the S&P 500. The -97.2 disparity indicates substantial underperformance relative to the benchmark. The relative disparity of 1.9 suggests that MRK is currently near its worst historical performance compared to VOO within the provided dataset.

### Alpha, Beta Analysis

| Year       | CAGR     | MDD      | Alpha    | Beta   | Cap(B) |
| ---------- | -------- | -------- | -------- | ------ | ------ |
| 2015-2017  | 5.0%     | 58.2%    | -24.0%   | -0.0   | 134.8  |
| 2016-2018  | 43.0%    | 66.4%    | 25.0%    | -0.1   | 183.1  |
| 2017-2019  | 40.0%    | 66.4%    | 11.0%    | 0.3    | 217.9  |
| 2018-2020  | 20.0%    | 66.4%    | 0.0%     | 0.3    | 196.0  |
| 2019-2021  | -1.0%    | 65.6%    | -50.0%   | 0.3    | 192.4  |
| 2020-2022  | 13.0%    | 69.5%    | 11.0%    | 0.3    | 278.6  |
| 2021-2023  | 31.0%    | 69.5%    | 13.0%    | 0.3    | 273.8  |
| 2022-2024  | -7.0%    | 69.5%    | -33.0%   | 0.2    | 249.8  |
| 2023-2025  | -55.0%   | 61.4%    | -102.0%  | 0.4    | 203.2  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  MRK has experienced fluctuating growth rates, with significant declines in the most recent periods (2022-2025).
*   **MDD (Maximum Drawdown):** High MDD values indicate substantial risk, with potential for significant losses.
*   **Alpha:** The consistently negative Alpha values, particularly in recent years, suggest MRK is underperforming relative to its risk-adjusted expected return based on the benchmark.
*   **Beta:** Beta values hovering around 0.3-0.4 indicate MRK's price is less volatile than the market.
*   **Cap(B):** The company's market capitalization has fluctuated, reflecting market sentiment and company performance.

### 2. Recent Stock Price Movements

*   **Current Price:** 80.93
*   **Previous Close:** 82.39
*   **Change:** -1.77
*   **5-Day Moving Average:** 80.5777
*   **20-Day Moving Average:** 80.0289
*   **60-Day Moving Average:** 79.169

**Analysis:** The recent price decrease (-1.77) suggests a short-term downward trend. The 5-day moving average being above the 20-day moving average, and both above the 60-day moving average, suggests a potential short-term upward trend, but the recent price drop warrants caution.

### 3. Technical Indicators

*   **MRI (Market Risk Indicator):** 0.3301 (Low Risk)
*   **RSI (Relative Strength Index):** 46.15
*   **PPO (Percentage Price Oscillator):** 0.2382
*   **Hybrid Signal:** cash\_0% Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Delta\_Previous\_Relative\_Divergence:** 1.7 (+) (Short-term Increase)
*   **Expected Return (%):** -545.9%

**Analysis:**

*   **MRI:** The low-risk MRI suggests relatively stable market conditions for MRK.
*   **RSI:** An RSI of 46.15 is neutral, not indicating overbought or oversold conditions.
*   **PPO:** The PPO value suggests a short-term upward trend.
*   **Hybrid Signal:** The signal recommends buying a portion of cash (80%) with caution, aligning with the low-risk MRI.
*   **Delta\_Previous\_Relative\_Divergence:**  The positive change in relative disparity suggests short-term improvement compared to the S&P 500, but it's a small consolation given the overall underperformance.
*   **Expected Return:** The extremely negative expected return (-545.9%) is a significant red flag, indicating a potentially substantial underperformance compared to the S&P 500 over a 2-year investment horizon.
*   **Price Change:** The price drop is a noteworthy event.

### 4. Recent News & Significant Events

*   **[2025-07-03]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-02]:** Analyst discussions on performance and outlook.
*   **[2025-07-01]:** Notable stock volatility.
*   **[2025-07-05]:** Expert advice to monitor news and announcements.

**Analysis:** The news suggests potential significant catalysts affecting MRK, including volatility and analyst scrutiny. Investors should closely monitor company announcements and news for specific details.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue       |
| ---------- | ---- | ------------- |
| 2025-05-02 | 2.01 | 15.53 B$      |
| 2024-11-06 | 1.25 | 16.66 B$      |
| 2024-08-05 | 2.15 | 16.11 B$      |
| 2024-05-03 | 1.88 | 15.78 B$      |
| 2025-05-02 | 1.88 | 15.78 B$      |

**Analysis:** The earnings data reveals fluctuations in both EPS (Earnings Per Share) and Revenue. While there were periods of strong EPS, there's inconsistency. Revenue has also fluctuated, indicating potential challenges in maintaining stable growth. Note: there are duplicate entries

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
| ------------ | -------- | ------------- |
| 2025-03-31   | $15.53B  | 77.98%        |
| 2024-12-31   | $15.62B  | 75.50%        |
| 2024-09-30   | $16.66B  | 75.51%        |
| 2024-06-30   | $16.11B  | 76.76%        |
| 2024-03-31   | $15.78B  | 77.56%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
| ------------ | -------- | -------- |
| 2025-03-31   | $48.34B  | 10.51%   |
| 2024-12-31   | $46.31B  | 8.08%    |
| 2024-09-30   | $44.50B  | 7.09%    |
| 2024-06-30   | $43.58B  | 12.52%   |
| 2024-03-31   | $40.36B  | 11.80%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue has fluctuated, peaking in Q3 2024. The profit margins are consistently high, indicating strong cost management and pricing power.
*   **Capital and Profitability:** Equity has generally increased, demonstrating asset growth. The ROE (Return on Equity) shows volatility, reflecting changes in profitability relative to equity.

### 7. Comprehensive Analysis & Summary

Based on the provided data, here's a summary of the key findings:

*   **Underperformance:** MRK has significantly underperformed the S&P 500, with a substantial negative disparity.
*   **Financial Health:**  High profit margins and growing equity are positive indicators. However, fluctuating revenues and ROE raise concerns.
*   **Technical Signals:** Technical indicators are mixed, with a recent price decrease and a neutral RSI, offset by a PPO indicating a potential upward trend.
*   **Market Risk:** The low MRI suggests relatively stable market conditions for MRK.
*   **News & Events:** Recent news highlights significant developments that could impact the stock, including volatility and analyst scrutiny.
*   **Expected Return:** The extremely negative expected return is a major concern.

**Overall Recommendation:**

Given the significant underperformance, negative expected return, and recent volatility, a cautious approach to MRK is warranted. Investors should closely monitor upcoming news, company announcements, and earnings reports before making any investment decisions. While the financial health of the company appears solid in terms of profit margins and equity growth, the underperformance relative to the market cannot be ignored.
